Ora, a leading global contract research organization (CRO) specializing in ophthalmic research, has announced a strategic recapitalization by The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact.
“The Vistria Group’s investment underscores their commitment to advancing cutting-edge therapies and supporting diversity in specialized clinical research. Ora’s leadership in ophthalmic clinical research positions us well to continue delivering life-enhancing treatments worldwide,” said Natasha Latif, Partner for Healthcare at The Vistria Group.
Stuart Abelson, Ora’s President, Chairman & CEO, will transition to the board of directors to focus on vision, strategy, customer relationships, and organizational culture. Paul Colvin, Ora’s Chief Operating Officer, will assume the role of CEO, bringing over 30 years of experience in leading CROs.
Stuart Abelson emphasized, “Ora’s renowned brand in ophthalmology research is built on our commitment to excellence and patient-centric innovation. With The Vistria Group’s support, we are poised to scale our global operations and advance technologies to drive the next generation of ophthalmic products.”
Paul Colvin added, “Our team’s dedication to delivering high-quality, reproducible data is pivotal in advancing our clients’ products efficiently. We are excited about the future with The Vistria Group, ensuring continuity and excellence in our services.”
About Ora:
Ora is the world’s leading full-service ophthalmic drug and device development firm, with a global presence spanning the United States, United Kingdom, Australia, and Asia. With over 45 years of experience, Ora has facilitated more than 85 product approvals, partnering with a diverse range of clients from startups to global pharmaceutical and device companies. Ora’s expertise in clinical models, methodologies, and regulatory strategies is backed by a team of ophthalmic experts, R&D professionals, and management executives dedicated to maximizing the value of new product initiatives.
